

研究成果の刊行に関する一覧表

【書籍】

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
茂木精一郎	SSc指尖潰瘍治療アップデート	宮地良樹, 常深祐一郎, 鶴田大輔	Whats new? in 皮膚科学 2020-2021	メディカルレビュー社	日本	2020	pp. 168-169

【雑誌】

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Fujimoto M, Asai J, Asano Y, Ishii T, Iwata Y, Kawakami T, Koderu M, Abe M, Amano M, Ikegami R, Isei T, Isogai Z, Ito T, Inoue Y, Irisawa R, Ohtsuka M, Omoto Y, Kato H, Kadono T, Kaneko S, Kanoh H, Kawaguchi M, Kukino R, Kono T, Koga M, Sakai K, Sakurai E, Sarayama Y, Shintani Y, Tanioka M, Tanizaki H, Tsujita J, Doi N, Nakanishi T, Hashimoto A, Hasegawa M, Hayashi M, Hirosaki K, Fujita H, Fujiwara H, Maekawa T, Matsuo K, Madokoro N, Motegi SI, Yatsushiro H, Yamasaki O, Yoshino Y, Pavoux AJL, Tachibana T, Ihn H; Japanese Dermatological Association Guidelines.	Wound, pressure ulcer and burn guidelines - 4: Guidelines for the management of connective tissue disease/vasculitis-associated skin ulcers.	J Dermatol.	47(10)	1071-1109	2020
Utsunomiya A, Hasegawa M, Oyama N, Asano Y, Endo H, Fujimoto M, Goto D, Ishikawa O, Kawaguchi Y, Kuwana M, Ogawa F, Takahashi H, Tanaka S, Sato S, Takehara K, Ihn H.	Clinical course of Japanese patients with early systemic sclerosis: A multicenter, prospective, observational study.	Mod Rheumatol	31 (1)	162-170	2021
Chunyan Zhao, Takashi Matsushita, Vinh Thi Ha Nguyen, Momoko Tennichi, Manabu Fujimoto, Kazuhiko Takehara, Yasuhiro Hamaguchi	CD22 and CD72 contribute to the development of scleroderma in a murine model	J Dermatol Sci	97(1)	66-76	2020
Toyama S, Yamashita T, Saigusa R, Miura S, Nakamura K, Hirabayashi M, Miyagawa T, Fukui Y, Omatsu J, Yoshizaki A, Sato S, Asano Y.	Decreased serum cathepsin S levels in patients with systemic sclerosis-associated interstitial lung disease.	J Dermatol.	47(9)	1027-1032	2020
Ebata S, Yoshizaki A, Fukasawa T, Asano Y, Oba K, Sato S.	Rapid decrease of serum surfactant protein-D levels predicts the reactivity of rituximab therapy in systemic sclerosis-associated interstitial lung disease.	J Dermatol.	47(7)	796-800	2020
Aozasa N, Hatano M, Saigusa R, Nakamura K, Takahashi T, Toyama T, Sumida H, Tamaki Z, Maki H, Minatsuki S, Komuro I, Sato S, Asano Y.	Clinical significance of endothelial vasodilatory function evaluated by EndoPAT in patients with systemic sclerosis.	J Dermatol.	47(6)	609-614	2020
Miyagawa T, Taniguchi T, Saigusa R, Fukayama M, Takahashi T, Yamashita T, Hirabayashi M, Miura S, Nakamura K, Yoshizaki A, Sato S, Asano Y.	Fli1 deficiency induces endothelial adipsin expression, contributing to the onset of pulmonary arterial hypertension in systemic sclerosis.	Rheumatology (Oxford)	59(8)	2005-2015	2020
Yamamoto T, Ito T, Asano Y, Sato S, Motegi SI, Ishikawa O, Matsushita T, Takehara K, Makino T, Okiyama N, Fujimoto M, Jinnin M, Ihn H.	Characteristics of Japanese patients with eosinophilic fasciitis: A brief multicenter study.	J Dermatol.	47(12)	1391-1394	2020
Maki H, Kubota K, Hatano M, Minatsuki S, Amiya E, Yoshizaki A, Asano Y, Morita H, Sato S, Komuro I.	Characteristics of Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis and Anticentriole Autoantibodies.	Int Heart J.	61(2)	413-418	2020
Fukui Y, Miyagawa T, Toyama S, Omatsu J, Hirabayashi M, Nakamura K, Yoshizaki A, Sato S, Asano Y.	Serum delta-like 4 levels: A possible association with interstitial lung disease in systemic sclerosis.	J Dermatol.	47(4)	e136-e137	2020
Asano Y, Sato S.	Localized scleroderma-like lesions induced by the Köbner phenomenon in a patient with systemic sclerosis positive for anticentromere antibody.	Eur J Dermatol.	30(4)	431-432	2020
Aozasa N, Miyazaki M, Hayakawa J, Tamaki T, Hamaguchi Y, Sato S, Asano Y.	Case of systemic sclerosis with multiple primary malignancies in whom anti-RNA polymerase III antibody was detected by immunoprecipitation.	J Dermatol.	47(7)	e269-e270	2020
Nakamura K, Sato S, Asano Y.	Overlapping systemic sclerosis and sarcoidosis with mutually exclusive disease activities: a case report and analysis of previous studies.	Eur J Dermatol.	30(1)	50-52	2020
Toyama S, Sato S, Asano Y.	Localized scleroderma histologically characterized by liquefaction degeneration and upper dermis fibrosis: a possible association with chemotherapy.	Clin Exp Dermatol.	45(5)	632-634	2020
Nakamura K, Ichimura Y, Tamaki Z, Yoshizaki A, Sato S, Asano Y.	Acute exacerbation of interstitial lung disease with onset of myositis in systemic sclerosis patients: a report of two cases.	Scand J Rheumatol.	49(3)	247-248	2020
Asano Y.	The Pathogenesis of Systemic Sclerosis: An Understanding Based on a Common Pathologic Cascade across Multiple Organs and Additional Organ-Specific Pathologies.	J Clin Med.	9	E2687	2020

Asano Y, Varga J.	Rationally-based therapeutic disease modification in systemic sclerosis: Novel strategies.	Semin Cell Dev Biol.	101	146-160	2020
Omatsu J, Saigusa R, Miyagawa T, Fukui Y, Toyama S, Awaji K, Ikawa T, Norimatsu Y, Yoshizaki A, Sato S, Asano Y.	Serum S100A12 levels: possible association with skin sclerosis and interstitial lung disease in systemic sclerosis.	Exp Dermatol.	30(3)	409-415	2021
Ikawa T, Miyagawa T, Fukui Y, Toyama S, Omatsu J, Awaji K, Norimatsu Y, Watanabe Y, Yoshizaki A, Sato S, Asano Y.	Association of serum CXCL12 levels with arthropathy in patients with systemic sclerosis.	Int J Rheum Dis.	24(2)	260-267	2021
Kotani H, Yoshizaki A, Matsuda KM, Norimatsu Y, Kuzumi A, Fukayama M, Fukasawa T, Ebata S, Yoshizaki-Ogawa A, Asano Y, Oba K, Sato S.	Serum calponin 3 levels in patients with systemic sclerosis: possible association with skin sclerosis and arthralgia.	J Clin Med.	10(2)	280	2021
Kuzumi A, Yoshizaki A, Ebata S, Fukasawa T, Yoshizaki-Ogawa A, Asano Y, Oba K, Sato S.	Serum TARC levels in patients with systemic sclerosis: clinical association with interstitial lung disease.	J Clin Med.	10(4)	660	2021
Matsuda KM, Yoshizaki A, Kotani H, Kuzumi A, Fukayama M, Fukasawa T, Ebata S, Yoshizaki-Ogawa A, Asano Y, Oba K, Sato S.	Clinical significance of anti-U1 ribonucleoprotein antibody in anti-topoisomerase I antibody-positive systemic sclerosis patients: a retrospective observational study.	Arch Clin Biomed Res.	5(1)	76-84	2021
Matsuda KM, Yoshizaki A, Kotani H, Norimatsu Y, Kuzumi A, Fukayama M, Fukasawa T, Ebata S, Yoshizaki-Ogawa A, Asano Y, Oba K, Sato S.	Serum heat shock protein 27 levels in patients with systemic sclerosis: a possible biomarker of skin sclerosis.	J Eur Acad Dermatol Venereol.	35(2)	e157-e159	2021
Yuki F, Nakamura K, Hirabayashi M, Miyagawa T, Toyama S, Omatsu J, Awaji K, Ikawa T, Norimatsu Y, Yoshizaki A, Sato S, Asano Y.	Serum vasohibin-1 levels: a potential marker of dermal and pulmonary fibrosis in systemic sclerosis.	Exp Dermatol.	doi: 10.1111/exd.14321.	Online ahead of print.	2021
Awaji K, Miyagawa T, Fukui Y, Toyama S, Omatsu J, Norimatsu Y, Ikawa T, Watanabe Y, Yoshizaki A, Sato S, Asano Y.	A potential contribution of decreased serum galectin-10 levels to systemic inflammation and pulmonary vascular involvement in systemic sclerosis.	Exp Dermatol.	doi: 10.1111/exd.14320.	Online ahead of print.	2021
Ikawa T, Miyagawa T, Fukui Y, Minatsuki S, Maki H, Inaba T, Hatano M, Toyama S, Omatsu J, Awaji K, Norimatsu Y, Watanabe Y, Yoshizaki A, Sato S, Asano Y.	Association of serum CCL20 levels with pulmonary vascular involvement and primary biliary cholangitis in patients with systemic sclerosis.	Int J Rheum Dis.	24(5)	711-718	2021
Saigusa R, Toyama T, Ichimura Y, Taniguchi T, Yoshizaki A, Sato S, Asano Y.	A case of systemic sclerosis complicated with portal hypertension.	J Clin Rheumatol.	doi: 10.1097/RHU.0000000000001633.	Online ahead of print.	2020
Norimatsu Y, Miyagawa T, Fukui Y, Omatsu J, Toyama S, Awaji K, Ikawa T, Watanabe Y, Yoshizaki A, Sato S, Asano Y.	Serum levels of tissue factor pathway inhibitor: potential association with Raynaud's phenomenon and telangiectasia in patients with systemic sclerosis.	J Dermatol.	doi: 10.1111/1346-8138.15893.	Online ahead of print.	2021
Ebata S, Yoshizaki A, Oba K, Ueda K, Uemura Y, Watadani T, Fukasawa T, Miura S, Asano Y, Okiyama N, Kodera M, Hasegawa M, Sato S.	Safety and efficacy of rituximab in systemic sclerosis: a double-blind, parallel-group comparison, investigators initiated clinical trial (DESIREs).	Lancet Rheumatol.	in press		2021
Ly NTM, Ueda-Hayakawa I, Nguyen CTH, Huynh NM, Kishimoto I, Fujimoto M, Okamoto H.	Imbalance toward TFH 1 cells playing a role in aberrant B cell differentiation in systemic sclerosis.	Rheumatology	60(3)	1553-1562	2021
Nomura Y, Ueda-Hayakawa I, Yamazaki F, Ozaki Y, Hamaguchi Y, Takehara K, Okamoto H	A case of anti-RuvBL1/2 antibody-positive systemic sclerosis overlapping with myositis	Eur J Dermatol.	30(1)	52-53	2020
Saito A, Ichimura Y, Kubota N, Tanaka R, Nakamura Y, Fujisawa Y, Watanabe R, Ishitsuka Y, Fujimoto M, Okiyama N.	Interferon-g-stimulated apoptotic keratinocytes promote sclerodermatous changes in chronic graft-versus-host disease.	J Invest Dermatol.	141(6)	1473-1481	2020
Yamashita K, Kawasaki A, Matsushita T, Furukawa H, Kondo Y, Okiyama N, Nagaoka S, Shimada K, Sugii S, Katayama M, Hirohata S, Okamoto A, Chiba N, Suematsu E, Setoguchi K, Migita K, Sumida T, Tohma S, Hamaguchi Y, Hasegawa M, Sato S, Kawaguchi Y, Takehara K, Tsuchiya N.	Association of functional (GA)n microsatellite polymorphism in the FLI1 gene with susceptibility to human systemic sclerosis.	Rheumatology (Oxford)	59(11)	3553-3562	2020
Shimizu T, Saito C, Watanabe M, Ishii R, Kawamura T, Nagai K, Fujita A, Kaneko S, Kai H, Morito N, Usui J, Yokosawa M, Kondo Y, Inoue S, Okiyama N, Yamagata K.	Anti-PM/Scl Antibody-positive Systemic Sclerosis Complicated by Multiple Organ Involvement.	Intern Med.	60(7)	1101-1107	2020
Takagi K, Kawamoto M, Higuchi T, Tochimoto A, Harigai M, Kawaguchi Y.	Single nucleotide polymorphisms of the HIF1A gene are associated with susceptibility to pulmonary arterial hypertension in systemic sclerosis and contribute to SSc-PAH disease severity.	Int J Rheum Dis	23	674-680	2020
Jinnin M, Ohta A, Ishihara S, Amano H, Atsumi T, Fujimoto M, Kanda T, Kawaguchi Y, Kawakami A, Mimori T, Minura T, Muro Y, Sano H, Shimizu J, Takeuchi T, Tanaka Y, Yamamoto K, Sumida T, Kohsaka H	First external validation of sensitivity of the European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria for idiopathic inflammatory myopathies with a Japanese cohort.	Ann Rheum Dis	79	387-392	2020

Miyamae T, Hanaya A, Kawamoto M, Tani Y, Kawaguchi Y, Yamanaka H	Diagnostic rate of autoinflammatory diseases evaluated by fever patterns in pediatric- and adult- onset patients	J Clin Rheumatol	26	60-62	2020
Tani Y, Kishi T, Miyamae T, Kawamoto M, Kawaguchi Y, Taniguchi A, Yamanaka H	The evaluation of gene polymorphisms associated with autoinflammatory syndrome in patients with palindromic rheumatism complicated by intermittent hydrarthrosis.	Clin Rheumatol	39	841-845	2020
Hirahara S, Katsumata Y, Kawasumi H, Kawaguchi Y, Harigai M	Serum levels of soluble programmed cell death protein 1 and soluble programmed cell death protein ligand 2 are increased in systemic lupus erythematosus and associated with the disease activity	Lupus	29	686-696	2020
Matucci-Cerinic M, Bruni C, Allamore Y, Clementi M, Dagna L, Damjanov N, De Paulis A, Denton CP, Distler O, Fox D, Furst DE, Khanna D, Krieg T, Kuwana M, Lee EB, Li, Pillai S, Wang Y, Zeng X, and Taliani G	Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management	Ann. Rheum. Dis	79(6)	724-726	2020
380. Nagaraja V, Matucci-Cerinic M, Furst DE, Kuwana M, Allamore Y, Denton CP, Raghu G, McLaughlin V, Rao PS, Seibold JR, Pauling J, Whitfield ML, and Khanna D	Current and future outlook on disease modification and defining low disease activity in systemic sclerosis	Arthritis Rheumatol	72(7)	1049-1058	2020
Yamasaki Y, and *Kuwana M	Nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease	Expert Rev. Clin. Immunol	16(6)	547-559	2020
383. Inoue Y, Kaner RJ, Guiot J, Maher TM, Tomassetti S, Moiseev S, Kuwana M, and Brown KK	Diagnostic and prognostic biomarkers for chronic fibrosing interstitial lung diseases with a progressive phenotype	Chest	158(2)	646-659	2020
Ota Y and *Kuwana M	Endothelial cells and endothelial progenitor cells in pathogenesis of systemic sclerosis	Eur. J. Rheumatol	7(suppl 3)	S139-146	2020
Hamaguchi Y, Kuwana M, and Takehara K	Performance evaluation of a commercial line blot assay system for detection of myositis- and systemic sclerosis-related autoantibodies	Clin. Rheumatol	39(11)	3489-3497	2020
388. Khanna D, Lin CJF, Furst DE, Goldin J, Kim G, Kuwana M, Allamore Y, Matucci-Cerinic M, Distler O, Shima Y, van Laar J, Spotswood H, Wagner B, Siegel J, Jahreis A, and Denton CP	Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial.	Lancet Respir. Med	8(10)	963-974	2020
*Kuwana M, Ogura T, Makino S, Homma S, Kondoh Y, Saito A, Ugai H, Gahlemann M, Takehara K, and Azuma A	Nintedanib in patients with systemic sclerosis associated interstitial lung disease: A Japanese population analysis of the SENSICIS trial	Mod. Rheumatol	31(1)	141-150	2021
Highland KB, Distler O, Kuwana M, Allamore Y, Assassi S, Azuma A, Bourdin A, Denton CP, Distler JHW, Hoffmann-Vold AM, Khanna D, Mayes MD, Raghu G, Vonk MC, Gahlemann M, Clerisme-Beaty E, Girard M, Stowasser S, Zoz D, and Maher TM on behalf of the SENSICIS trial investigators	Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: subgroup analysis of the SENSICIS trial	Lancet Respir. Med	9(1)	96-106	2021
Nawata T, Shirai Y, Suzuki M, and *Kuwana M	Chest wall muscle atrophy as a contributory factor for forced vital capacity decline in systemic sclerosis-interstitial lung disease.	Rheumatology (Oxford)	60(1)	250-255	2021
Tamura Y, Kumamaru H, Abe K, Satoh T, Miyata H, Ogawa A, Tanabe N, Hatano M, Yao A, Tsuzino I, Fukuda K, Kimura H, Kuwana M, Matsubara H, Tatsumi K, and the Japan PH Registry (JAPHR) Network	Improvements in French risk stratification score were correlated with reductions in mean pulmonary artery pressure in pulmonary arterial hypertension: A subanalysis of the Japan Pulmonary Hypertension Registry (JAPHR)	BMC Pulm. Med	21(1)	28	2021
*Kuwana M, Hasegawa M, Fukue R, Shirai Y, Ishikawa O, Endo H, Ogawa F, Goto D, Kawaguchi Y, Sato S, Ihn H, and Takehara K	Initial predictors of skin thickness progression in patients with diffuse cutaneous systemic sclerosis: results from a multicentre prospective cohort in Japan.	Mod. Rheumatol	31(2)	386-393	2021
Azuma A, Chung L, Behera D, Chung M, Kondoh Y, Ogura T, Okamoto M, Swarnakar RN, Zeng X, Zou H, Meng L, Gahlemann M, Alves M, and Kuwana M on behalf of the SENSICIS trial investigators	Efficacy and safety of nintedanib in Asian patients with systemic sclerosis-associated interstitial lung disease: subgroup analysis of the SENSICIS trial.	Respir. Invest	59(2)	252-259	2021
Orlandi M, Landini N, Bruni C, Colagrande S, Pignone AM, Matucci-Cerinic M, and Kuwana M	Infection or autoimmunity? The clinical challenge of interstitial lung disease in systemic sclerosis during COVID 19 pandemic	J. Rheumatol	48(5)	790-792	2021
Utsunomiya A, Hasegawa M, Oyama N, Asano Y, Endo H, Fujimoto M, Goto D, Ishikawa O, Kawaguchi S, Kuwana M, Ogawa F, Takahashi H, Tanaka S, Sato S, Takehara T, Ihn H.	Clinical course and treatment outcome of Japanese patients with early progressive systemic sclerosis: a multicenter, prospective, observational study	Mod Rheumatol	31(1)	162-170	2021
Kuwana M, Hasegawa M, Fukue R, Shirai Y, Ishikawa O, Endo H, Ogawa F, Goto D, Kawaguchi Y, Sato S, Ihn H, Takehara K.	Initial predictors of skin thickness progression in patients with diffuse cutaneous systemic sclerosis: Results from a multicentre prospective cohort in Japan	Mod Rheumatol	31(2)	386-393	2021
Tani S, Kaminaka C, Nishiyama K, Yariyama A, Nakatani Y, Inaba Y, Kunimoto K, Yamamoto Y, Makino K, Makino T, Jinnin M.	yRNA3 up-regulation in cultured dermal fibroblasts and yRNA4 down-regulation in the sera of scleroderma patients.	J Dermatol Sci.	102(1)	68-71	2021

Tabata K, Jinnin M, Furukawa K, Tani S, Okuhira H, Mikita N, Fujii T.	Finger sweating levels evaluated by video capillaroscopy system are increased in patients with systemic sclerosis compared to pre-clinical stage patients.	Drug Discov Ther.	14(6)	325-329	2021
Shimada S, Makino K, Jinnin M, Sawamura S, Kawano Y, Ide M, Kajihara I, Makino T, Fukushima S, Ihn H.	CXCL17-mediated downregulation of type I collagen via MMP1 and miR-29 in skin fibroblasts possibly contributes to the fibrosis in systemic sclerosis.	J Dermatol Sci.	100(3)	183-191	2020
Utsunomiya N, Utsunomiya A, Chino T, Hasegawa M, Oyama N.	Gene silencing of extracellular matrix protein 1 (ECM1) results in phenotypic alterations of dermal fibroblasts reminiscent of clinical features of lichen sclerosus.	J Dermatol Sci.	100(2)	99-109	2020
Kuwana M, Hasegawa M, Fukue R, Shirai Y, Ishikawa O, Endo H, Ogawa F, Goto D, Kawaguchi Y, Sato S, Ihn H, Takehara K.	Initial predictors of skin thickness progression in patients with diffuse cutaneous systemic sclerosis: Results from a multicentre prospective cohort in Japan.	Mod Rheumatol.	31(2)	386-393	2021
Utsunomiya A, Oyama N, Hasegawa M.	Potential Biomarkers in Systemic Sclerosis: A Literature Review and Update.	J Clin Med.	9(11)	3388	2020
Kawabata K, Makino T, Makino K, Kajihara I, Fukushima S, Ihn H.	IL-16 expression is increased in the skin and sera of patients with systemic sclerosis.	Rheumatology (Oxford).	59(3)	519-523	2020
Oshikawa Y, Makino T, Nakayama M, Sawamura S, Makino K, Kajihara I, Aoi J, Masuguchi S, Fukushima S, Ihn H.	Increased CD27 expression in the skins and sera of patients with systemic sclerosis.	Intractable Rare Dis Res.	9(2)	99-103	2020
Sekiguchi A, Inoue Y, Yamazaki S, Uchiyama A, Ishikawa O, Kuribayashi S, Uraoka T, Hara K, Yamaguchi K, Maeno T, Uchida M, Koyama H, Motegi S.	Prevalence and clinical characteristics of earlobe crease in systemic sclerosis: Possible association with vascular dysfunction.	Journal of Dermatology	47(8)	870-875	2020
Yamamoto T, et al.	Characteristics of Japanese patients with eosinophilic fasciitis: a multicenter brief study.	J Dermatol	47	1391-1394	2020
Watanabe Y, Yamamoto M, Yamamoto T.	A case of eosinophilic fasciitis and generalized morphea overlap.	Dermatol Online J	26	13030	2020
長谷川 稔	【臓器線維症を科学する-病態解明と治療法開発への展望】 臓器特異性と共通性、全身性強皮症の皮膚線維化の機序と治療標的	週刊医学のあゆみ	275(10)	1143-1148	2020
尾山徳孝、宇都宮夏子、長谷川 稔	白斑や抗甲状腺抗体などの自己免疫異常を伴った外陰部硬化性苔癬	皮膚病診療	42(4)	310-331	2020
長谷川 稔	診療の秘訣 膠原病の診断 “爪のまわりをみる”	Modern Physician	40(3)	290	2020
波多野将	心筋障害の評価とその管理	リウマチ科	第63巻第5号	515-523	2020
牧野貴充	【冬の皮膚病】治療 全身性強皮症の皮膚潰瘍に対するボセンタン治療の効果と実際	皮膚病診療	42(12)	1046-1052	2020
茂木 精一郎、石川 治	難治性指尖潰瘍の評価とその管理	リウマチ科	63	493-499	2020
茂木 精一郎	全身性強皮症に伴う末梢循環障害に対するボツリヌス毒素局所注入療法	月刊BIO INDUSTRY	37	95-103	2020